Goodyear F2G Corsair

F2G and Shionogi Present Full Data Set from Pivotal Phase 2b Study at Trends in Medical Mycology (TIMM) 2023 Demonstrating Positive Therapeutic Responses in Patients with Invasive Fungal Infections Treated with Oral Olorofim

Retrieved on: 
Saturday, October 21, 2023
Standard of care, TIMM, Immunodeficiency, Congress, MD, EORTC, Doctor of Philosophy, Fungus, Research, Coccidioidomycosis, DRC, Shionogi, UZ Leuven, Hematology, OASIS, Scopulariopsis, World Health Organization, Risk, Antifungal, Medical Mycology, ACM, Fungal infection, Goodyear F2G Corsair, Patient, Infection, Birth control, Pharmaceutical industry, Coccidioides, F2G

These findings were submitted as a late breaking abstract and exceptionally accepted for an oral presentation during the 11th Congress on Trends in Medical Mycology (TIMM) 2023 held in Athens, Greece, from 20-23 October 2023.

Key Points: 
  • These findings were submitted as a late breaking abstract and exceptionally accepted for an oral presentation during the 11th Congress on Trends in Medical Mycology (TIMM) 2023 held in Athens, Greece, from 20-23 October 2023.
  • F2G and Shionogi & Co., Ltd. are collaborating to develop and commercialise olorofim, bringing the novel antifungal therapy to patients with invasive fungal infections.
  • F2G has commercial responsibility for olorofim in North America, and Shionogi has commercial responsibility for olorofim in Europe and Asia Pacific.
  • F2G and Shionogi are currently enrolling patients with invasive aspergillosis in a global Phase 3 study (OASIS) to compare treatment with olorofim versus AmBisome® followed by standard of care ( NCT05101187 ).

UPDATE – F2G Wins Investment Deal of the Year Bionow 2022 Award

Retrieved on: 
Friday, March 17, 2023
QIAGEN, Shionogi, Patient, Goodyear F2G Corsair, Fungal infection, Conference, Pharmaceutical industry

F2G was awarded Investment Deal of the Year at the Bionow awards ceremony which was held at the iconic Concorde Conference Centre in Manchester, United Kingdom, on March 16, 2023.

Key Points: 
  • F2G was awarded Investment Deal of the Year at the Bionow awards ceremony which was held at the iconic Concorde Conference Centre in Manchester, United Kingdom, on March 16, 2023.
  • The Investment Deal of the Year award, sponsored by QIAGEN, is in recognition of F2G's strategic collaboration with Shionogi Co., Ltd. to develop and commercialize a new class of antifungal drugs for invasive fungal infections in Europe and Asia, bringing the drug to patients F2G alone would not have reached.
  • The deal terms between F2G Ltd., and Shionogi & Co. Ltd were notably above benchmarks for the antifungal space.
  • "We are honored to be recognized and celebrated by our peers with the prestigious award from Bionow.

F2G Wins Investment Deal of the Year Bionow 2022 Award

Retrieved on: 
Friday, March 17, 2023
QIAGEN, Shionogi, Patient, Goodyear F2G Corsair, Fungal infection, Conference, Pharmaceutical industry

F2G was awarded Investment Deal of the Year at the Bionow awards ceremony which was held at the iconic Concorde Conference Centre in Manchester, United Kingdom, on March 16, 2023.

Key Points: 
  • F2G was awarded Investment Deal of the Year at the Bionow awards ceremony which was held at the iconic Concorde Conference Centre in Manchester, United Kingdom, on March 16, 2023.
  • The Investment Deal of the Year award, sponsored by QIAGEN, is in recognition of F2G's strategic collaboration with Shionogi Co., Ltd. to develop and commercialize a new class of antifungal drugs for invasive fungal infections in Europe and Asia, bringing the drug to patients F2G alone would not have reached.
  • The deal terms between F2G Ltd., and Shionogi & Co. Ltd were notably above benchmarks for the antifungal space.
  • "We are honored to be recognized and celebrated by our peers with the prestigious award from Bionow.

Invasive Aspergillosis Drug Pipeline Report 2022: Comprehensive Insights on Active Companies and Pipeline Drugs Featuring F2G, SCYNEXIS, Pulmocide, & TFF Pharmaceuticals - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 20, 2022
Health, Pharmaceutical, Aspergillosis, Clinical trial, MDR, European Medicines Agency, QIDP, Breakthrough therapy, Research, III, News, NDA, Candida auris, Auris, Disease, Acquisition, Discovery, Infection, Drug of last resort, FDA, Therapy, Goodyear F2G Corsair, II, IV, Pharmaceutical industry, Aspergillus, Pneumocystidomycetes

This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Invasive Aspergillosis pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Invasive Aspergillosis pipeline landscape.
  • The assessment part of the report embraces, in depth Invasive Aspergillosis commercial assessment and clinical assessment of the pipeline products under development.
  • This segment of the Invasive Aspergillosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Invasive Aspergillosis R&D.

F2G Announces Data from Phase 2b Study at ID Week 2022 Showing Positive Therapeutic Response in Patients with Invasive Fungal Infections Treated with Olorofim

Retrieved on: 
Friday, October 21, 2022
News, European Medicines Agency, Nausea, Aspergillosis, SOC, Infection, US Foods, QIDP, Mycosis, Diarrhea, Patient, Fungus, Hematology, Standard of care, Hepatotoxicity, Mortality, Coccidioidomycosis, BID, Food, Scedosporiosis, ACM, Vomiting, DHODH, Food and Drug Administration, MD, Doctor of Philosophy, Immunosuppression, Safety, CNS, GLOBE, Goodyear F2G Corsair, Central nervous system, Antifungal, FDA, Breakthrough therapy, UZ Leuven, Pharmaceutical industry, Scopulariopsis, Overalls, Coccidioides, Aspergillus, Scedosporium

Approximately 75% of patients in this analysis had moderate to high levels of immunosuppression, with about half suffering from fungal infections due to Aspergillus.

Key Points: 
  • Approximately 75% of patients in this analysis had moderate to high levels of immunosuppression, with about half suffering from fungal infections due to Aspergillus.
  • Data came from 100 patients with proven invasive fungal infection or probable pulmonary invasive aspergillosis (IA).
  • Mortality remains unacceptably high in patients with severe and life-threatening fungal infections being treated with currently available therapies.
  • Olorofim has been granted Qualified Infectious Disease Product (QIDP) designation for invasive aspergillosis, invasive scedosporiosis, invasive lomentosporiosis, coccidioidomycosis, invasive disease due to Scopulariopsis species, and invasive fusariosis.

F2G appoints Camilla Soenderby to Board of Directors

Retrieved on: 
Wednesday, September 15, 2021
Goodyear F2G Corsair, European Medicines Agency, Board of directors, DHODH, NDA, QIDP, Mycosis, Antifungal, R, Board, CEO, Patient, Aspergillosis, SVP, McKinsey & Company, Growth, Takeda, Schering-Plough, Partnership, Infection, Camilla, Acquisition, Chronic pulmonary aspergillosis, Orotomide, Coccidioidomycosis, AbbVie, Pharmaceutical industry, Management

MANCHESTER, England, PRINCETON, N.J.and VIENNA, Sept. 15, 2021 /PRNewswire/ -- F2G Ltd, a clinical-stage biopharmaceutical company focused on rare life-threatening fungal diseases with a high unmet medical need, today announces the appointment of Camilla Soenderby as a Non-Executive Director to its Board of Directors with immediate effect.

Key Points: 
  • MANCHESTER, England, PRINCETON, N.J.and VIENNA, Sept. 15, 2021 /PRNewswire/ -- F2G Ltd, a clinical-stage biopharmaceutical company focused on rare life-threatening fungal diseases with a high unmet medical need, today announces the appointment of Camilla Soenderby as a Non-Executive Director to its Board of Directors with immediate effect.
  • Patrick Vink, Chairman of F2G Ltd, said: "On behalf of the whole board I am very pleased to welcome Camilla to F2G.
  • Camilla began her career as a management consultant at McKinsey & Co. focused on the biopharmaceutical and medical devices industries.
  • F2G is a world-leading biotech company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections.

F2G appoints Camilla Soenderby to Board of Directors

Retrieved on: 
Wednesday, September 15, 2021
Goodyear F2G Corsair, European Medicines Agency, Board of directors, DHODH, NDA, QIDP, Mycosis, Antifungal, R, Board, CEO, Patient, Aspergillosis, SVP, McKinsey & Company, Growth, Takeda, Schering-Plough, Partnership, Infection, Camilla, Acquisition, Chronic pulmonary aspergillosis, Orotomide, Coccidioidomycosis, AbbVie, Pharmaceutical industry, Management

MANCHESTER, England, PRINCETON, N.J. and VIENNA, Sept. 15, 2021 /PRNewswire/ -- F2G Ltd, a clinical-stage biopharmaceutical company focused on rare life-threatening fungal diseases with a high unmet medical need, today announces the appointment of Camilla Soenderby as a Non-Executive Director to its Board of Directors with immediate effect.   

Key Points: 
  • MANCHESTER, England, PRINCETON, N.J.and VIENNA, Sept. 15, 2021 /PRNewswire/ -- F2G Ltd, a clinical-stage biopharmaceutical company focused on rare life-threatening fungal diseases with a high unmet medical need, today announces the appointment of Camilla Soenderby as a Non-Executive Director to its Board of Directors with immediate effect.
  • Patrick Vink, Chairman of F2G Ltd, said: "On behalf of the whole board I am very pleased to welcome Camilla to F2G.
  • Camilla began her career as a management consultant at McKinsey & Co. focused on the biopharmaceutical and medical devices industries.
  • F2G is a world-leading biotech company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections.